Get the Stockscreener App
2.60
4.00%
0.10
Polaryx Therapeutics Inc stock is traded at $2.60, with a volume of 146.86K.
It is up +4.00% in the last 24 hours and up +15.04% over the past month.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
See More
Previous Close:
$2.50
Open:
$2.52
24h Volume:
146.86K
Relative Volume:
0.76
Market Cap:
$129.60M
Revenue:
-
Net Income/Loss:
$-6.48M
P/E Ratio:
-18.98
EPS:
-0.137
Net Cash Flow:
$-5.30M
1W Performance:
+15.04%
1M Performance:
+15.04%
6M Performance:
+7.88%
1Y Performance:
+0.00%
1-Day Range:
$2.22
$2.68
1-Week Range:
$1.99
$2.68
52-Week Range:
$1.86
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Name
Polaryx Therapeutics Inc
Sector
Industry
Phone
201-940-7236
Address
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
2.60 | 111.16M | 0 | -6.48M | -5.30M | -0.137 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Initiated | Maxim Group | Buy |
Polaryx Therapeutics Inc Stock (PLYX) Latest News
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Sahm
Polaryx Therapeutics (PLYX) cuts losses as cash rises to $11.5M - Stock Titan
Polaryx Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Coverage Initiated at Raymond James Financial - MarketBeat
PLYX Initiated Coverage by Raymond James -- Strong Buy Rating An - GuruFocus
Raymond James Initiates Polaryx Therapeutics at Strong Buy - marketscreener.com
Raymond James initiates Polaryx Therapeutics stock with strong buy By Investing.com - Investing.com South Africa
Raymond James initiates Polaryx Therapeutics stock with strong buy - Investing.com Nigeria
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - 富途牛牛
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polaryx Therapeutics, Inc. SEC Filing (Jul 28, 2026) - Stock Titan
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Se - GuruFocus
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Set to Buy - GuruFocus
Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential - Investing.com Canada
PLYX|Polaryx Therapeutics Ord Shs|Price:2.096|Chg%:-0.024 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – NASDAQ:PLYX - TradingView
Polaryx Therapeutics Ord Shs (PLYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLYX|Polaryx Therapeutics Ord Shs|Price:2.220|Chg%:+0.020 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – BOATS:PLYX - TradingView
Polaryx Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
Polaryx Therapeutics, Inc. Files Form 8-K as Emerging Growth Company on NASDAQ (PLYX) – July 2026 - Minichart
Polaryx Therapeutics' Lisa Bollinger resigns as Chief Medical Officer - TradingView
Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026 - marketscreener.com
Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis - kalkine.ca
Polaryx Sets 2026 Virtual Annual Shareholder Meeting - TipRanks
Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline - Stock Titan
Polaryx Therapeutics (PLYX) Edges Higher Amidst Narrow Trading RangeIndex Put Call - dars.gov.et
What is HC Wainwright's Forecast for PLYX Q2 Earnings? - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
PLYX News Today | Why did Polaryx Therapeutics stock drop today? - MarketBeat
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating - Investing.com
PLYX Initiates Coverage On Polaryx Therapeutics -- Price Target Set at $7.00 - GuruFocus
Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co. - Moomoo
Polaryx Therapeutics (PLYX) Stock Analysis Report | Financials & Insights - Benzinga España
Operating cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8 - TradingView
Free cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8 - TradingView
Polaryx Therapeutics (PLYX) Surges 7.7%: Momentum Builds Above Key SupportInstitutional Sentiment - DonanımHaber
Polaryx Therapeutics (PLYX) Holds Steady Near Support as Technical Indicators Signal ConsolidationSector Sentiment - dars.gov.et
Enterprise value to EBIT forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Enterprise value to revenue forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Price to sales forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Price to earnings forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Polaryx Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLYX) - TradingView
PLYX Forecast — Price Target — Prediction for 2027 - TradingView
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Ord Shs (PLYX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polaryx Therapeutics Ord Shs - TradingKey
Polaryx Therapeutics Inc Stock (PLYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):